Skip to main content

Overdose with modified‐release paracetamol results in delayed and prolonged absorption of paracetamol

Buy Article:

$43.00 plus tax (Refund Policy)

A modified‐release formulation of paracetamol is currently available in Australasia and marketed under a number of different trade names. These include: Panadol Osteo, Panadol Extend Tablets, and Duatrol SR. We report four cases of intentional overdose with this formulation resulting in delay to peak plasma paracetamol concentrations and prolonged paracetamol absorption. Physicians must be aware that a single plasma paracetamol estimation four or more hours post‐ingestion may not be adequate in the risk assessment of patients requiring treatment with N‐acetylcysteine (NAC). Current Australasian guidelines for the management of modified‐release paracetamol overdose advise empiric commencement of NAC if the suspected ingested dose is greater than 10 grams or 200 mg/kg (whichever is the least), an initial plasma paracetamol concentration should be assayed four or more hours post‐ingestion and a second assay should be estimated four hours after the first. Treatment with NAC should continue if either concentration falls above the paracetamol treatment nomogram line. With massive ingestions of this paracetamol formulation (>50 grams) plasma concentrations may be elevated for several days and prolonged treatment with NAC is recommended. When modified‐release paracetamol overdose is suspected a clinical toxicologist or Poisons Information Centre should be consulted to help guide management decisions.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: deliberate self‐poisoning; overdose; paracetamol; sustained‐release tablets

Document Type: Research Article

Affiliations: Clinical and Experimental Toxicology Unit, Department of Emergency Medicine, Prince of Wales Hospital, Sydney, New South Wales, Australia

Publication date: 2010-01-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more